ES2123570T3 - Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma. - Google Patents

Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma.

Info

Publication number
ES2123570T3
ES2123570T3 ES92917640T ES92917640T ES2123570T3 ES 2123570 T3 ES2123570 T3 ES 2123570T3 ES 92917640 T ES92917640 T ES 92917640T ES 92917640 T ES92917640 T ES 92917640T ES 2123570 T3 ES2123570 T3 ES 2123570T3
Authority
ES
Spain
Prior art keywords
elam
asthma
molecula
endothelium
leukocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917640T
Other languages
English (en)
Inventor
Robert H Gundel
Craig D Wegner
L Gordon Letts
C Wayne Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Baylor College of Medicine, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMA
Application granted granted Critical
Publication of ES2123570T3 publication Critical patent/ES2123570T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DEL ASMA EN UN PACIENTE UTILIZANDO UN AGENTE SELECCIONADO DE UN GRUPO QUE CONSISTE EN: (A) UN ANTICUERPO CAPAZ DE UNIRSE AL ELAM-1; (B) UN FRAGMENTO CAPAZ DE UNIRSE AL ELAM-1; (C) ELAM-1, ESTANDO EN GRAN PARTE LIBRE DE CONTAMINANTES NATURALES; (D) UN DERIVADO FUNCIONAL DE ELAM-1; (E) UN ANTICUERPO CAPAZ DE UNIRSE A UN RECEPTOR ELAM-1; (F) UN FRAGMENTO DEL ANTICUERPO (E), EL FRAGMENTO CAPAZ DE UNIRSE A UN RECEPTOR ELAM-1; (G) UN RECEPTOR ELAM-1, EN GRAN PARTE CAPAZ DE ESTAR LIBRE DE CONTAMINANTES NATURALES; Y (H) UN DERIVADO FUNCIONAL DE UN RECEPTOR ELAM-1.
ES92917640T 1991-07-31 1992-07-31 Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma. Expired - Lifetime ES2123570T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73863391A 1991-07-31 1991-07-31

Publications (1)

Publication Number Publication Date
ES2123570T3 true ES2123570T3 (es) 1999-01-16

Family

ID=24968819

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917640T Expired - Lifetime ES2123570T3 (es) 1991-07-31 1992-07-31 Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma.

Country Status (12)

Country Link
US (1) US5843441A (es)
EP (1) EP0551501B1 (es)
JP (1) JPH06502195A (es)
KR (1) KR100252621B1 (es)
AT (1) ATE173503T1 (es)
AU (1) AU663332B2 (es)
CA (1) CA2083273A1 (es)
DE (1) DE69227618T2 (es)
DK (1) DK0551501T3 (es)
ES (1) ES2123570T3 (es)
HU (1) HU215549B (es)
WO (1) WO1993002702A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5911196A (en) * 1995-06-13 1997-01-09 Nisshin Oil Mills, Ltd., The Antiasthmatic agent
US6008203A (en) * 1995-07-14 1999-12-28 Glycotech Corp. Methods for treatment of EGF receptor associated cancers
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
AU2002308628A1 (en) * 2001-05-08 2002-11-18 Blanchette Rockefeller Neurosciences Institute Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
MX2022009130A (es) * 2020-01-24 2022-08-22 Pfizer Anticuerpos anti-e-selectina, composiciones y metodos de uso.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927188T2 (de) * 1988-11-14 1997-04-24 Brigham & Womens Hospital Antikörper, spezifisch gegen elam-1 sowie deren verwendung
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands

Also Published As

Publication number Publication date
ATE173503T1 (de) 1998-12-15
CA2083273A1 (en) 1993-02-01
WO1993002702A1 (en) 1993-02-18
HUT69623A (en) 1995-09-28
KR930702025A (ko) 1993-09-08
HU215549B (hu) 1999-01-28
EP0551501B1 (en) 1998-11-18
KR100252621B1 (ko) 2000-09-01
DK0551501T3 (da) 1999-08-02
AU2441092A (en) 1993-03-02
EP0551501A1 (en) 1993-07-21
DE69227618D1 (de) 1998-12-24
US5843441A (en) 1998-12-01
EP0551501A4 (en) 1993-09-22
DE69227618T2 (de) 1999-05-06
AU663332B2 (en) 1995-10-05
HU9300928D0 (en) 1993-06-28
JPH06502195A (ja) 1994-03-10

Similar Documents

Publication Publication Date Title
DK0584136T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
BE2016C024I2 (es)
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69328550T2 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
FI972093A0 (fi) Jäteveden käsittelymenetelmä ja -laitos
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DK0473671T3 (da) Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
DE69118359D1 (de) Optisch reines r(-)albuterol zur behandlung von asthma
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ES2123570T3 (es) Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma.
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ATE278781T1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
DE69111457T2 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
DE69413952T2 (de) Extraktion von zellgebundenem protein von bordetella
BG101325A (en) Use of muramyl peptide compounds
DE59611353D1 (de) Transketolase-verwandtes protein
NO974687L (no) Kondenserte <beta>-carboliner
FR2664599B1 (fr) Vinylsulfonyl pristinamycine et sa preparation.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 551501

Country of ref document: ES